How Common are MASLD and MASH
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in the U.S., affecting an estimated 38% of adults. This condition […]
We have achieved ISO27001:2022 certification
Fibronostics is proud to announce that we have achieved ISO27001:2022 certification, another significant milestone in our company’s journey towards excellence
LIVERSTAT is now a Notified Medical Device
We are thrilled to announce that LIVERSTAT, our software as medical device (SaMD) has been officially listed as a Class
Fibronostics Team at SHC 2024
Our team had an incredible experience during the Singapore Hepatology Conference 2024 held at Grand Hyatt Hotel, Singapore .We’ve had
Meet our Team at AASLD 2024!
Join Fibronostics at the 75th Annual AASLD Liver Meeting from November 15-19 in beautiful San Diego, CA, where we’ll be
Application of LIVERFASt to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome
Aims for the study: To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting hepatic steatosis in